Larger blood sugar swings are linked to worse cancer outcomes, more treatment problems, and poorer survival. A 2026 review brought together studies on diabetes, blood sugar, and cancer. It focused on how blood sugar control relates to cancer growth, treatment, and survival. This was a review of existing evidence, not a new treatment test. The source summary gives no study counts or numbers showing the size of these links. For our community, Glucose Variability (CV%) is the key topic. It describes how much glucose readings swing compared with their average. The review linked bigger swings and poor blood sugar control to worse outcomes. These included more treatment-related problems and greater difficulty staying with cancer treatment. Some cancer drugs also appeared to work less well. Very low blood sugar was another warning sign linked to poorer survival. Average blood sugar does not tell the whole story. The review notes that HbA1c (Hemoglobin A1c), a longer-term blood sugar measure, can miss swings during cancer treatment. Real-Time Glucose (CGM) uses a wearable sensor to follow glucose throughout the day. The authors see this as a promising way to spot lows and support steadier levels. But the review does not prove that reducing swings improves cancer survival. For BioSocial members, this supports looking at patterns alongside bloodwork averages. Comparing your own readings over time may add useful context. Community notes can include the dates tracked and whether cancer treatment was underway. This review does not set a target percentage or predict anyone’s cancer risk from one reading. What have your glucose patterns shown that your bloodwork averages missed?